PANAVANCE THERAPEUTICS

panavance-therapeutics-logo

Panavance Therapeutics is a clinical-stage pharmaceutical company that advances the development of GP-2250 novel oncology therapeutics focused on improving the effectiveness of cancer treatments.

#SimilarOrganizations #People #Website #More

PANAVANCE THERAPEUTICS

Social Links:

Industry:
Pharmaceutical Therapeutics

Founded:
2021-01-01

Address:
Berwyn, Pennsylvania, United States

Country:
United States

Website Url:
http://www.panavance.com

Total Employee:
11+

Status:
Active

Contact:
+1.610.922.1910


Similar Organizations

galimedix-therapeutics-logo

Galimedix Therapeutics

Galimedix Therapeutics is an ophthalmic pharmaceutical company that develops novel and transformative treatments.

ocunexus-therapeutics-logo

Ocunexus Therapeutics

Ocunexus Therapeutics is a biopharmaceutical company that develops therapeutics for unmet clinical needs in ophthalmology.

yamo-pharmaceuticals-logo

Yamo Pharmaceuticals

Yamo Pharmaceuticals is a clinical-stage pharmaceutical company that develops L1-79, a novel therapy for Autism spectrum disorder.

Current Employees Featured

cynthia-collins_image

Cynthia Collins
Cynthia Collins Lead Director @ Panavance Therapeutics
Lead Director
2021-12-01

Official Site Inspections

http://www.panavance.com Semrush global rank: 5.18 M Semrush visits lastest month: 1.56 K

  • Host name: 31.25.154.104.bc.googleusercontent.com
  • IP address: 104.154.25.31
  • Location: United States
  • Latitude: 38.6583
  • Longitude: -77.2481
  • Timezone: America/New_York

Loading ...

More informations about "Panavance Therapeutics"

Panavance - Novel Cancer Therapeutic - Giving Patients New Hope

It is so refreshing to work with an organization that not only shares wholeheartedly in our mission to improve survival and quality of life for patients, ... Panavance Therapeutics Announces โ€ฆSee details»

Leadership - Panavance Therapeutics

Greg Bosch brings over 35 years in healthcare to Panavance with global leadership of commercial, operations, and R&D teams. His general management experience in the life โ€ฆSee details»

About Panavance Therapeutics

Panavance Therapeutics is a privately held, clinical-stage pharmaceutical company developing a novel oncology asset, misetionamide (also known as GP-2250). Panavance, a US Delaware company located in Berwyn, PA, was โ€ฆSee details»

Panavance Therapeutics - Crunchbase Company Profile & Funding

Organization. Panavance Therapeutics . Connect to CRM . Save . Summary. People. Technology. Signals & News. Similar Companies. ... Panavance Therapeutics is a clinical-stage โ€ฆSee details»

Panavance Therapeutics Inc. Management Team | Org Chart

The Panavance Therapeutics Inc. management team includes Greg Bosch (Chairman and CEO), Erich Platzer (Board Member), and Cindy Collins (Lead Director). Get Contact Info for All โ€ฆSee details»

Panavance Therapeutics Inc. | LinkedIn

Panavance Therapeutics Inc. is a US, clinical-stage pharmaceutical company established in 2021 by the Swiss-based Avensis Pharma AG, a subsidiary of Ed.See details»

Panavance Details IND Prep Ahead Of FDA Submission For โ€ฆ

Oct 23, 2024 Panavance CEO Greg Bosch discusses the companyโ€™s pursuit of a second trial for misetionamide, walking us through IND preparations, CRO selection, and securing funding. ...See details»

Panavance Therapeutics, Inc. - Drug pipelines, Patents, Clinical โ€ฆ

Explore Panavance Therapeutics, Inc. with its drug pipeline, therapeutic area, technology platform, 9 news, Disease Domain:Endocrinology and Metabolic Disease ...See details»

Panavance Therapeutics - Contacts, Employees, Board Members, โ€ฆ

Panavance Therapeutics is a clinical-stage pharmaceutical company that develops novel therapeutics for effective cancer treatments. ... Pricing. Log In. Log In. Experience the new โ€ฆSee details»

Panavance Therapeutics to Present at the Biotechnology

May 24, 2023 Panavance, a US Delaware company, is located in Berwyn, PA. It was founded in 2021 and is a subsidiary of Swiss privately held Ed. Geistlich Söhne AG für Chemische Industrie.See details»

Panavance Therapeutics Inc. - VentureRadar

Panavanceโ€™s lead program, GP-2250, is a tumor cell selective and broadly active small molecule with a unique mechanism of action designed to disrupt energy metabolism, resulting in cancer โ€ฆSee details»

Panavance Therapeutics

It is so refreshing to work with an organization that not only shares wholeheartedly in our mission to improve survival and quality of life for patients, but has truly unique science that ... We are โ€ฆSee details»

Panavance Therapeutics Company Profile | Management and

Panavance Therapeutics Inc. is a privately held, clinical-stage pharmaceutical company developing a novel oncology asset, GP-2250 (also known as misetionamide). Panavance was โ€ฆSee details»

Panavance Therapeutics Inc. Created to Transform Cancer Treatment

Jan 11, 2022 Panavance is not responsible for the contents of third-party websites. About Panavance Therapeutics Inc. Panavance Therapeutics Inc. is a US, clinical-stage โ€ฆSee details»

Panavance Therapeutics | Life Sciences PA - Default Site

In June 2021, Panavance Therapeutics Inc, a clinical stage biotechnology company focused on novel oncology therapeutics, was incorporated in Delaware. The Companyโ€™s lead product โ€ฆSee details»

Panavance Therapeutics - PitchBook

Panavance Therapeutics General Information Description. Operator of a clinical-stage pharmaceutical company intended to improve the effectiveness of cancer treatments and the โ€ฆSee details»

Resource Center - Panavance Therapeutics

Panavance Therapeutics to Present at the Biotechnology Innovation Organization (BIO) International Convention. Read Release . Press Release โ€“ April 17, 2023 ... Greg Bosch, โ€ฆSee details»

Panavance Therapeutics - Overview, News & Similar companies

Panavance Therapeutics Inc. is a privately held, clinical-stage pharmaceutical company developing a novel oncology asset, GP-2250 (also known as mi setionamide). Panavance was โ€ฆSee details»

Panavance Therapeutics Inc. Created to Transform Cancer Treatment

Jan 24, 2022 The new company is focused on developing GP-2250, a novel cancer therapeutic with a unique mechanism of action. Excerpt from the Press Release: Panavance Therapeutics โ€ฆSee details»

Interim data reveals potential of new pancreatic cancer drug

Oct 23, 2024 Panavance Therapeutics revealed the interim data from its Phase I clinical study at the 2024 Visceral Medicine Congress in Leipzig, Germany. The Phase I dose escalation โ€ฆSee details»

linkstock.net © 2022. All rights reserved